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PC12 cellFibroblast growth factor 1 (FGF1) is a differentiation and survival factor for neuronal cells both in vitro and in
vivo. FGF1 activities can be mediated not only by paracrine and autocrine pathways involving FGF receptors
but also by an intracrine pathway, which is an underestimated mode of action. Indeed, FGF1 lacks a secretion
signal peptide and contains a nuclear localization sequence (NLS), which is consistent with its usual
intracellular and nuclear localization. To progress in the comprehension of the FGF1 intracrine pathway in
neuronal cells, we examined the role of the nuclear translocation of FGF1 for its neurotrophic activity as well
as for its protective activity against p53-dependent apoptosis. Thus, we have transfected PC12 cells with
different FGF1 expression vectors encoding wild type or mutant (Δ NLS) FGF1. This deletion inhibited both
FGF1 nuclear translocation and FGF1 neurotrophic activity (including differentiation and serum-free cell
survival). We also show that endogenous FGF1 protection of PC12 cells against p53-dependent cell death
requires FGF1 nuclear translocation. Strikingly, wild type FGF1 is found interacting with p53, in contrast to
the mutant FGF1 deleted of its NLS, suggesting the presence of direct and/or indirect interactions between
FGF1 and p53 pathways. Thus, we present evidences that FGF1 may act by a nuclear pathway to induce
neuronal differentiation and to protect the cells from apoptosis whether cell death is induced by serum
depletion or p53 activation.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Fibroblast growth factor 1 (FGF1), one of the 22 members of the
FGF family, is a multipotent factor involved in proliferation,
differentiation and cell survival [1–3]. It is widely distributed in the
adult peripheral and central nervous systems. FGF1 expression
increase during neuronal development and a high level of FGF1 is
detected in various adult neuronal cell types [4–6]. For example, all
neuronal layers of the retina express FGF1 and this expression
matches the sequential differentiation of the different layers [6–8]
suggesting a direct role of FGF1 in the retina development. Indeed,
suppression of FGF1 expression by antisense oligonucleotides in
embryonic chick retinal cells inhibits neuronal differentiation and
survival [9]. FGF1 is a differentiation and survival factor for various
neuronal cells both in vitro and in vivo [9–14].
FGF activities are usually mediated in cells by autocrine and/or
paracrine pathways involving FGF receptors (FGF-R) with tyrosine33 1 39253655.
ll rights reserved.kinase activities. Exogenous FGF (externally added FGF) binds to FGF-
R, thus promoting the phosphorylation and activation of these
receptors, which initiates various intracellular signaling pathways,
such as Ras/MAP kinases, PI3K/AKT and PLC-γ pathways [15].
However, FGF1 lacks a secretion signal peptide and contains a nuclear
localization sequence (NLS), consistent with being an intracellular
and a nuclear localization in most of the cell-types tested [16]. Further
studies of endogenous FGF1 activities have revealed the presence of
an FGF1 intracrine pathway involved in the proliferation, differenti-
ation and survival of different cell-types [3,9,12,13,16–19].
In PC12 cells, we have previously shown that during the
differentiation process induced by exogenous FGF, endogenous FGF1
and FGF2 expression increases [12]. We also demonstrated that
overexpression of FGF1 by transfection is sufﬁcient to induce
differentiation and serum-free survival of these cells by a mechanism
independent of the MAP kinases pathway. Recently, we have shown
that exogenous FGF1 protected PC12 cells from p53-dependent
apoptosis [14]. FGF1 decreased phosphorylation, nuclear transloca-
tion and transcriptional activities of the tumor suppressor p53
following DNA damage induced by etoposide treatment. In the
present study, we examined the role of the nuclear translocation of
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against p53-dependent apoptosis. For that purpose, we stably
transfected PC12 cells with different FGF1 expression vectors
encoding wild type FGF1 or mutant FGF1 deleted for the nuclear
translocation sequence KKPK. In PC12 cells, we showed that this
deletion inhibits FGF1 nuclear translocation and FGF1 neurotrophic
activity including differentiation and cell survival in the absence of
serum. We also showed that protection of PC12 cells against p53-
dependent cell death by endogenous FGF1 requires nuclear translo-
cation of this neuroprotective protein. The deletion of the NLS
sequence dramatically decreases wild type FGF1 effects, namely a
decrease of p53 stabilization and phosphorylation, an inhibition of
both p53-dependent trans-activation of puma and caspase activation
and, the interaction of FGF1 with p53. This study suggests that FGF1
may act through a nuclear pathway both to induce neuronal
differentiation and to protect cells from apoptosis, whether the cell
death signal is serum depletion or p53 activation.
2. Materials and methods
2.1. Cell cultures and drugs
PC12 cells, a rat pheochromocytoma derived cell line [20], were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 10% fetal calf serum (FCS), 5% horse serum (HS), 100 μg/
ml penicillin, 100 U/ml streptomycin and 1% Glutamax at 37 °C in a
humidiﬁed atmosphere of 5% CO2 as previously described [12,14].
PC12 cells transfected with inducible FGF1 expression vectors (pLK-
FGF1-140, pLK-FGF1-134 and pLK-FGF1-127) were maintained in
DMEM supplemented with 10% fetal calf serum and 5% horse serum
which were both depleted in glucocorticoid by ﬁxation onto 1%
charcoal vegetal Norit pulver (Prolabo) and 0.1% dextran T70
(Pharmacia). In transfected cells, FGF1 expression was induced by
5×10−7 M dexamethasone (Tebu). Etoposide (50 μg/ml, Sigma,
E1383) was used to induce p53-dependent apoptosis.
2.2. FGF1 eukaryotic expression vectors
Wild type and mutant FGF1 coding regions were subcloned into a
glucocorticoid-responsive vector (pLK), which contained a MMTV-
LTR promoter variant and the neomycin resistance gene [21]. We had
previously cloned the sequence coding for human FGF1 (aa 21 to 154)
in this vector (pLK-FGF1-134) and isolated stable transfected PC12
cells with this vector [12]. We also cloned the sequence coding for
human FGF1 (aa 15 to 154) in the pLK vector (pLK-FGF1-140), as a
control. To examine the effect of FGF1 nuclear translocation, we
cloned the sequence coding for a mutant human FGF1 (aa 28 to 154)
deleted of its putative nuclear localization signal (KKPK, aa 23 to 26)
in the pLK vector (pLK-FGF1-127).
2.3. PC12 cells transfection
PC12 cells were transfected with 10 μg of the different vectors
(pLK-Neo, pLK-FGF1-140, pLK-FGF1-134, pLK-FGF1-127) and 60 μl of
Lipofectin reagent (Invitrogen) in 100-mm diameter Petri dishes as
previously described [12]. Two days after transfection, the cells were
trypsinized and replated in four 100-mm diameter Petri dishes with
selection medium (0.5 mg/ml geneticin in culture medium). After 15
days of selection, geneticin resistant colonies appeared whatever the
expression vector used. For each transfection, two plates were
maintained in selection medium to isolate stable clones for further
analyses. The other two plates were treated with 5×0−7 M
dexamethasone in selection medium to induce FGF1 expression.
After 10 days of treatment, cell morphology was observed by phase
contrast microscopy. The number of non-differentiated clones
(composed of cells with no neuritis extension or extensions smallerthan the size of the soma) and differentiated clones (composed of cells
extending neuritis longer than the size of the cell body) were
quantiﬁed for each expression vector. This experimentwas performed
twice with similar results. To simplify the text and ﬁgures, PC12 cells
transfected by pLK-Neo, pLK-FGF1-140, pLK-FGF1-134 and pLK-FGF1-
127 were named Neo, WTα, WTβ and TM, respectively.
2.4. Serum-free cell survival analysis
PC12 cell lines (PC12, Neo, WTα, WTβ and TM) were plated on
poly-L-lysine-coated 12-multiwell plates at a density of 105 cells/ml
in low serum medium (0.8 % FCS, 0.4% HS) with 5×10−7 M
dexamethasone. After 4 days, the cells were cultured in serum-free
medium in presence of 5×10−7M dexamethasone for 1–2weeks. Cell
viability was estimated using the crystal violet method (0.1% crystal
violet, 0.1 M citric acid) after different times of treatment (from 0 to
15 days). The percentage of surviving cells, corresponding to the
proportion of viable attached cells (with intact nuclear staining), was
expressed as a percentage of the initial population (present at the
beginning of the serum-free culture). Cell morphology was observed
by phase contrast microscopy and pictures were taken after different
times of serum-free culture.
2.5. p53-dependent apoptosis analysis
PC12 cell lines (PC12, Neo, WTα, WTβ and TM) were plated in
12-multiwell plates at a density of 7×104 cells/ml with 5×10−7 M
dexamethasone. When the cells reached 70% conﬂuence, 50 μg/ml
etoposide was added to the medium to induce p53-dependent
apoptosis (as previously described [14]). Cell viability was estimat-
ed using the crystal violet method (0.1% crystal violet, 0.1 M citric
acid) after 24 to 48 h of etoposide treatment. The percentage of
surviving cells, corresponding to the proportion of viable attached
cells (with intact nuclear staining), was expressed as a percentage
of the initial population (present at the beginning of etoposide
treatment).
2.6. Immunocytochemistry
Transfected PC12 cells (Neo, WTα, WTβ and TM) were plated
onto poly-L-lysine-coated Lab-Tek chamber slides (Nunc) at a
density of 5×104 cells/ml in the presence or absence of 5×10−7 M
dexamethasone. After seven days of treatment, cells were ﬁxed with
4% paraformaldehyde, incubated with anti-FGF1 (1:100, polyclonal
anti-human FGF1, serum I4, gift from Lisa Oliver [22]) or with anti-
NF160 (1:200, monoclonal anti-Neuroﬁlament 160 kDa, clone
NN18, Sigma) in 0.3% Triton X-100, 1% milk PBS for 1 h. The
antigen-antibody complexes were ampliﬁed with anti-rabbit or
anti-mouse Ig biotinylated antibodies (1:100, Amersham) and then
revealed with Extravidin-TRITC conjugate (1:100, Sigma). Immu-
noreactive cells were observed with a Leitz's microscope and
photographed.
2.7. Nuclear and cytoplasmic fractions extraction
PC12 cell lines (Neo, WTα, WTβ and TM) were cultured for 3–5
days in the presence of 5×10−7 M dexamethasone. At 80%
conﬂuence, cells were lysed in 400 μl of cold buffer (10 mM Hepes,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT) in the presence
of proteases inhibitors (1 mM AEBSF-Boehringer). After 15 minutes of
incubation on ice, 25 μl of 10 % NP-40were added to the samples. After
10-second vortexing, samples were centrifuged for 30 s at 2000 g. The
supernatant (cytoplasmic fraction) was then harvested. The pellet
(nuclear fraction) was rinsed with 1 ml of PBS and resuspended in
150–300 μl of PBS. Proteins (1–20 μg) of cytoplasmic and nuclear
fractions were analyzed by Western blotting.
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PC12 cell lines (PC12, WTα and TM) were plated in 60-mm dishes
in the presence of 5×10−7 M dexamethasone. At 70% conﬂuence,
cells were incubated with 50 μg/ml etoposide and dexamethasone.
After different treatment times (0, 8 and 16 h), cells were harvested,
lysed and frozen at −20 °C. Proteins (20–40 μg) from etoposide-
treated cell lysates or from nuclear and cytoplasmic fractions (see
previous paragraph) were electrophoresed in NuPAGE 4-12 % Bis-Tris
polyacrylamide gels (Invitrogen) and transferred onto PVDF mem-
branes (Millipore). Blots were incubated with the primary antibody
(see below) overnight at 4 °C, and further incubated for 1 h with
peroxidase-conjugated antibodies (Biosystem). The primary antibo-
dies used were rabbit polyclonal anti-FGF1 (1:500, AB-32-NA, R&D
Systems), mousemonoclonal anti-p53 (1:100, Pab 122, gift fromDr. E.
May, IRSC, Villejuif, France), rabbit polyclonal anti-p53-P (Ser-15)
(1:200, Santa Cruz), goat polyclonal anti-PUMAα (1:200, N-19, Santa
Cruz), rabbit monoclonal anti-cleaved Caspase-3 (1:1000, Asp175,Fig. 1. Subcellular localization of FGF1. (A) PC12 cells were transfected with glucocorticoid
clones were isolated and named Neo, WTα, WTβ and TM, respectively. (B) Transfected PC1
seven days. FGF1 expression and localization was analyzed by immunocytochemistry using a
presence of 5×10−7 M dexamethasone for 3–5 days. Nuclear and cytoplasmic proteins were
fractions of the different cell lines.Cell Signaling), rat monoclonal anti-Tubulin (1:500, MAS078, Sera-
Lab) and rabbit polyclonal anti-Enolase (1:500, Santa Cruz). IgG
peroxidase-conjugated secondary antibodies were detected by ECL or
ECLplus kits depending on signal intensity (Amersham).
2.9. Immunoprecipitation analysis
PC12 cell lines (PC12, WTα and TM) were plated in 100-mm
dishes in the presence of 5×10−7 M dexamethasone. At 70%
conﬂuence, cells were incubated with 50 μg/ml etoposide and
dexamethasone. After 16 h treatment, cells were harvested, pelleted
and resuspended in lysis/immunoprecipitation buffer (250 mM NaCl,
1% NP40, 50 mM Hepes [pH 7], 5 mM EDTA, 0.5 mM DTT)
supplemented with Protease Inhibitor Cocktail (AEBSF, Roche). Cells
were incubated for 30 min on ice prior homogenization. Prior to
immunoprecipitation, 1.2 μg anti-p53 (Pab 122, gift from Dr. E. May,
IRSC, Villejuif, France) or anti-GFP (clones 7.1 and 13.1, Roche) were
coupled with protein G magnetic beads O/N at 4 °C. Protein G-responsive vectors pLK-Neo, pLK-FGF1-140, pLK-FGF1-134, pLK-FGF1-127 and stable
2 cell lines were cultured in the absence or presence of 5×10−7 M dexamethasone for
polyclonal anti-FGF1 antibody (I4). (C) Transfected PC12 cell lines were cultured in the
extracted and analyzed byWestern blot for FGF1 and Enolase detection in the different
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assess the background of aspeciﬁc binding proteins. Then, cell extracts
were incubated with protein G magnetic beads (pre-coupled with
anti-p53 or anti-GFP) for 4 h at 4 °C. After 5 washes with 0.1% PBS-
Tween, the immunoprecipitated proteins were eluted from the
magnetic beads by boiling in loading buffer (0.1 M DTT, 25% NuPage
LDS Sample Buffer, Invitrogen, diluted in PBS) for 5 min before
Western blot analysis.
3. Results
To determine the role of the nuclear localization of FGF1 for its
neurotrophic activity, we transfected PC12 cells with different FGF1Fig. 2. PC12 cell differentiation. (A, B) Neo, WTα, WTβ and TM transfected PC12 cells were tr
After 10 days of dexamethasone treatment, cell morphology was observed and the number o
expression vector (B). This experiment was performed twice with similar results. (C) Stable
5×10−7 M dexamethasone for 7 days. The presence of Neuroﬁlament 160 kDa, a different
(clone NN18).expression vectors encoding wild type FGF1 or a mutant FGF1 that is
deleted for the nuclear localization signal KKPK (aa 23 to 26). For that
purpose, we subcloned into a glucocorticoid-responsive vector (pLK)
the coding sequence of wild type FGF1s (aa 15 to 154 and aa 21 to 154)
and of the nuclear translocation mutant FGF1 (aa 28 to 154) to isolate
PC12 stable transfected cell lines respectivelynamedWTα,WTβ andTM
(Fig. 1A). The two wild type forms (WTα and β) correspond to the two
major forms of FGF1 (140 and 134 aa) which can be extracted from
tissues and which are currently used as recombinant factors for in vitro
experiments. As a control, the pLK-Neo vectorwas transfected to isolate
PC12Neo cell lines. Different stable cloneswere isolated for each vector.
The expression level and subcellular localization of FGF1 were analyzed
by immuno-cytochemistry (Fig. 1B) and by Western blot after nucleareated with 5×10−7 M dexamethasone in selection medium to induce FGF1 expression.
f non differentiated clones (A,1) and differentiated clones (A,2) were quantiﬁed for each
transfected PC12 cell lines (Neo, WTα, WTβ and TM) were cultured in the presence of
iation marker, was analyzed by immunocytochemistry using a monoclonal anti-NF160
Fig. 3. Serum-free cell survival. Stable transfected PC12 cell lines (Neo, WTα, WTβ and
TM) were cultured in presence of 5×10−7 M dexamethasone in serum-free medium
for eleven days. Cell morphology was observed by phase contrast microscopy (A) and
cell survival was quantiﬁed by crystal violet nuclei staining (B).
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previously described for native PC12 cells, the level of rat endogenous
FGF1 was too low to be detected by immunocytochemistry or western
blotting without heparin sepharose puriﬁcation [12]. InWTα, WTβ and
TM transfected PC12 cells, FGF1 (wild type and mutant) was only
detected in presence of dexamethasone (which induced MMTV-LTR
promoter of pLK vectors). It can be noticed that wild type and mutant
FGF1 are never detected in the conditioned medium of unstressed or
stressed PC12 cells even after heparin sepharose concentration
suggesting that these factors were actually not secreted (data not
shown). In WT (α or β) cells, FGF1 presented both nuclear and
cytoplasmic localization (Fig. 1B, C). In contrast, in TM cells mutated
FGF1 was principally detected in the cytoplasmic compartment. This
showed that deletion of the NLS (KKPK) signiﬁcantly decreases FGF1
nuclear translocation.
We then tested the differentiation activities of FGF1 (WT and
mutant) on a large population of PC12 transfected clones (about 200
clones per expression vector) after induced FGF1 expression by the
addition of 5×10−7 M dexamethasone for 10 days. Cellular
morphology was observed by phase contrast microscopy (Fig. 2A).
The number of non-differentiated clones (containing cells with no
neuritis extension or extensions smaller than cell size) and differen-
tiated clones (containing cells with neurites longer than cell size)
were quantiﬁed for each transfected expression vector. The expres-
sion of wild type FGF1 (WTα or β) induced the differentiation process
in 40 to 50% of the transfected clones, in contrast to mutant FGF1
(TM), which presented a basal level of differentiation similar to
control PC12 cells (Neo) (Fig. 2B). This result was conﬁrmed by
analysis of stable transfected cell lines. Only wild type FGF1 (WT α or
β) induced the differentiation of PC12 cells as detected by cell
morphology analysis and by immunocytochemistry detection of a
neuronal marker, expression of Neuroﬁlament 160 kDa (NF160) (Fig.
2C). FGF1 mutant transfected cell lines (TM), similarly to control cell
lines (Neo), presented neither a differentiated phenotype nor NF160
expression. Therefore, deletion of the nuclear translocation signal
signiﬁcantly decreases the differentiation activity of FGF1.
In an attempt to determine the pro-survival activity of nuclear
FGF1 in serum-free PC12 cell cultures, the different transfected cell
lines were cultured without serum (Fig. 3). After 11 days, PC12 cells
overexpressing the wild type FGF1 (WTα, WTβ) still survived in
serum-free media and presented a differentiated morphology, in
contrast to mutant-FGF1-transfected cells (TM) and control cells
(Neo). Thus, in the absence of serum wild type FGF1 (WTα and
WTβ) protects PC12 cells from cell death and the deletion of
nuclear localization signal strongly decreases this protection,
suggesting that FGF1 nuclear translocation is required for its
neurotrophic activity.
We recently showed that exogenous FGF1 (added to the culture
medium) protects PC12 cells from p53-dependent apoptosis [14]. In
the present study, we examined the activity of endogenous FGF1
(wild type and translocation mutant) in this cell death process. p53-
dependent apoptosis was induced by etoposide, a DNA damaging
agent as previously described [14] in both native and stably
transfected PC12 cell lines (Neo, WTα, WTβ and TM). After 28 h of
etoposide treatment, cell survival was analyzed (Fig. 4A). Over-
expression of wild type FGF1 (WTα and WTβ) protected PC12 cells
from p53-dependent apoptosis, in contrast to mutant FGF1 (TM).
Therefore, nuclear localization of FGF1 is important for the protection
activity of FGF1 against p53-dependent apoptosis.
We further examined the status of p53 (accumulation and
phosphorylation) in the different cell lines (PC12, WTα and TM).
Etoposide led to the increase of p53 protein level in PC12 cells and to
p53 phosphorylation on serine 15 (Fig. 4B), a post-translational
modiﬁcation that was previously correlated with an increase of p53
stability and transcriptional activity [14,23]. Wild type FGF1 (WTα)
prevented p53 accumulation and phosphorylation induced byetoposide. In the mutant-FGF1-transfected PC12 cells (TM), etopo-
side induced intermediate levels of p53 and p53-P, suggesting that
the deletion of the nuclear localization sequence partially inhibits
FGF1 activity on p53 accumulation and phosphorylation. In these cell
lines, we then examined p53-dependent transactivation of puma,
which encodes a pro-apoptotic BH3-only member of the Bcl-2
family. In mutant-FGF1-transfected cells (TM), like in native PC12
cells, etoposide treatment induced an increase of the levels of Puma
(Fig. 4C). However this increase was signiﬁcantly reduced in wild
type-FGF1-transfected cells (WTα). This result suggests that FGF1
nuclear localization is required for this factor to inhibit p53-
dependent trans-activation of puma. Then, we examined by Western
blot the cleavage of caspase-3, as a marker of the activation of the
cascade of caspases, in the different cell lines after etoposide
treatment (Fig. 4C). In mutant-FGF1-transfected cells (TM), like in
native PC12 cells, etoposide treatment induced the cleavage and
activation of caspase-3, however no cleaved caspase-3 can be
detected in wild type-FGF1-transfected cells (WTα). Thus, wild
type FGF1 inhibited p53-dependent activation of caspases and
protected the cells from apoptosis, while mutant FGF1 deleted for
its nuclear translocation sequence did not. Last, we explored
whether p53 and FGF1 could interact by immunoprecipitation
Fig. 4. p53-dependent apoptosis. Native PC12 cells and stable transfected PC12 cell lines (Neo, WTα, WTβ and TM) were cultured in the presence of 5×10−7 M dexamethasone.
Subconﬂuent cultures were treated with 50 μg/ml etoposide to induce p53-dependent apoptosis. (A) Cell viability after 28 h of etoposide treatment was quantiﬁed using the crystal
violet method. (B) Western blot analysis of p53 and p53-P (Ser-15) protein levels in PC12, WTα and TM cells treated with etoposide for 0, 8 and 16 h. (C) Western blot analysis of
Puma and cleaved caspase-3 (p17) protein levels in PC12, WTα and TM cells treated with etoposide for 0, 8 and 16 h. Tubulin was used as a control. Each result is representative of
three independent experiments.
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type FGF1 transfected cell lines in presence of etoposide, p53 was
immunoprecipitated with anti-p53 antibody but not with anti-GFP
antibody which was used as a negative control. In absence of
etoposide, the level of p53 is very low and the presence of the IgG
just upstream p53 hardens the detection of the oncosuppressor. We
then tested whether FGF1 co-immunoprecipates with p53 in the
three cell lines. As shown in Fig. 5, wild type FGF1 co-immunopre-
cipitated with p53 in the presence and in the absence (to a lesser
extend) of etoposide in contrast to mutant FGF1. In native PC12 cells,
the level of endogenous FGF1 is too low to detect any interaction
between p53 and FGF1. These data suggest that p53 interacts with
FGF1 only in the nuclear compartment. However, we cannot exclude
that the deletion of the NLS could modify the structure or
conformation of FGF1, thus affecting its ability to interact with
p53. All our data strongly suggest that nuclear localization of FGF1 is
required to inhibit the p53-dependent apoptotic process by direct or
indirect interactions.4. Discussion
We previously reported that endogenous FGF1 is a neurotrophic
factor for PC12 cells which induces both neuritis extension and
survival to serum starvation [12]. Recently, we showed that
exogenous FGF1 (added in the culture medium) protects PC12 cells
from p53-dependent apoptosis [14]. In the present study, we present
evidence that endogenous FGF1, which is localized in both nuclear
and cytoplasmic compartments, protects PC12 cells from p53-
dependent apoptosis. These data suggest that FGF1 induces PC12
cells differentiation as well as survival after serum depletion or p53
activation by an intracrine pathway. To progress in the comprehen-
sion of this pathway and to determine the role of FGF1 nuclear
localization, we tested different truncated forms of FGF1 (with or
without NLS). WTα and β correspond to the two major forms of FGF1
(140 and 134 aa) which can be extracted from tissues and which are
currently used as recombinant factor for in vitro experiments. Both
wild type forms presented the same nuclear and cytoplasmic
Fig. 5.Wild type FGF1 interacts with p53. Native and stably transfected PC12 cell lines
(WTα and TM) were cultured in the presence of 5×10−7 M dexamethasone and in
absence or presence of etoposide (16 h). Total cell extracts were subjected to
immunoprecipitation using anti-p53 or anti-GFP precoupled with Protein G Magnetic
Beads. Immunoprecipitated complexes (IP p53) were analyzed for the presence of p53
and FGF1 by immunoblotting. Equivalent amounts of anti-GFP immunoprecipitated
complexes (IP GFP), the IP supernatants (Sn IP p53 and Sn IP GFP) and the total cell
extracts were loaded as controls.
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study. The ﬁrst 14 residues (propeptide deleted in FGF1-140,WTα) or
20 residues (deleted in FGF1-134, WTβ) of the coding sequence of
FGF1 are not required for FGF1 neurotrophic activity and FGF1
protection against p53-dependent apoptosis. By contrast, deletion of
the ﬁrst 27 residues (FGF1-127, TM) modiﬁed both the subcellular
localization and the activity of this factor. The sequence deleted in
FGF1 TM by comparison to FGF1 WTβ (only seven residues) contains
the NLS (KKPK, aa 23 to 26) previously characterized by Imamura et
al. [16]. In PC12 cells, FGF1 TM was principally detected in the
cytoplasmic compartment and was unable to induce differentiation of
the PC12 cells as well as to protect them from serum depletion or p53-
dependent apoptosis, in contrast to wild-type forms of FGF1. Deletion
of the KKPK NLS inhibits FGF1 nuclear translocation both in PC12 cells
(of neuroendocrine cell type) and in 3T3 cells (murine ﬁbroblasts,
[16]) suggesting that KKPK-dependent FGF1 nuclear translocation
process is neither species nor tissue speciﬁc. Wesche and collabora-
tors [24] characterized a second putative NLS in the FGF1 coding
sequence located near its C-terminus. This second NLS is a bipartite
NLS consisting of clusters of lysines separated by a spacer of 10 amino
acids. Both NLSs (N-terminal NLS1 and C-terminal bipartite NLS2) are
able to target GFP to the nucleus when expressed in HeLa cells.
Mutation in either of the NLS impaired nuclear translocation of
exogenously added FGF1 in NIH3T3 cells. However, only the double
mutation (NLS1 and NLS2) decreases FGF1 efﬁciency in stimulating
DNA synthesis. In PC12 cells, deletion of only NLS1 impaired FGF1
nuclear translocation as well as its neurotrophic and p53-dependent
protection activities.We cannot exclude that NLS2 could participate to
FGF1 localization and activity in these cells. However, our results
suggest that NLS1 is required to FGF1 nuclear translocation and
activities in PC12 cells while NLS2 is not sufﬁcient for a nuclear
localization in theses cells.
The activity of thismutant FGF1was initially examinedby Imamura
et al. [16]. In endothelial and ﬁbroblast cells, addition of exogenous
FGF1 TM (namedHBGF-1U in [16]) induced neither DNA synthesis nor
cell growth in contrast to FGF1 WTβ (named HBGF-1α), suggesting
that FGF1 nuclear translocation is required for both activities.
However, both FGF1 TM and WTβ could induce the phosphorylation
of FGF1 receptors and stimulate c-fos expression, suggesting that these
two activitieswere insufﬁcient for the stimulation of DNA synthesis. Inmurine 3T3 cells, overexpression of FGF1 TM, but not FGF1 WTβ
overexpression, failed to trigger translocation of FGF1 to the nuclear
compartment and to induce a transformed phenotype [16]. More
recently, two laboratories examined the activity of thismutant FGF1 in
vitro and in vivo [25,26]. In vitro, mutant FGF1 (named aFGF28-154 in
[25]) added in the culture medium did not induce NIH3T3 or PC12 cell
proliferation, as assessed byMTT experiments, in contrast to wild type
FGF1. With dexamethasone-induced mouse thymocyte apoptosis
models developed in vitro and in vivo, the recombinant mutant FGF1
conserved its anti-apoptotic activity, which was slightly increased
compared to wild type FGF1. In vivo, this mutant FGF1 reduced
apoptosis in rat gut epithelium after ischemia-reperfusion injury [25]
and partially protected fromN-methyl-N-nitrosourea (MNU)-induced
rat retinal degeneration [26]. For both studies, Escherichia coli
recombinant wild type or mutant FGF1 were added in the culture
medium for in vitro studies or were injected for in vivo studies
involving the receptor-dependent pathway and/or internalization by
endocytosis process before intracrine and/or nuclear pathway
implication. In PC12 cells, we have previously shown that over-
expression of endogenous wild type FGF1 induced differentiation and
serum-free survival via an intracrine pathway independent of FGF
receptors and the MAP kinase cascade [12]. Thus, in the present study,
we focused our research on the potential alternative nuclear pathway
and compared activity of endogenously expressed wild type and
mutant FGF1.We showed that overexpression of FGF1 TM in PC12 cells
failed to translocate to the nuclear compartment and to induce
differentiation, serum-free survival and protection against p53-
dependent apoptosis in contrast to both WTα and WTβ FGF1s. It
suggests that FGF1 nuclear translocation is required for its neuro-
trophic activity and to inhibit p53-dependent apoptosis. In transfected
PC12 cells, whatever the form (wild type or mutant), whatever the
conditions of cultures (control or etoposide treated), we never
detected FGF1 in the culture medium even after heparin sepharose
concentration suggesting that this factor (WT or mutant) is not
secreted and did not act via a receptor-dependent process. It has been
reported that the structure of TM FGF1 could be less stable than WT
FGF1. However, a study of the Guimenez-Gallego laboratory examined
the three dimensional structure of this mutant (named FGF1127-154)
and concluded that the structure of this mutant could be even more
stable than the wild type protein and is similar to that of the wild type
except at site 1 of interaction with the cell membrane receptor [27]. In
PC12 cells, we never detected any signiﬁcant difference in expression
or stability of TMFGF1 compared toWT FGF1. In serum-freemedia, TM
FGF1 slightly increased PC12 cell survival. This result led us to the
hypothesis that either FGF1 could partially act in the cytoplasmic
compartment or that a small part of FGF1 can passively diffuse in the
nuclear compartment to inhibit serum-free apoptosis, even in absence
of its NLS domain. We have previously shown by Enzyme Immuno-
Assay [12] that a four fold increase of endogenous FGF1 is enough to
induce serum-free survival. In PC12 cells transfected with pLK
expression vector, the level of FGF1 is about ten to hundred fold
increased when compared to native endogenous FGF1 levels. Thus, if
only a small part of TMFGF1 could passively enter the nucleus, itwould
be enough to partially protect the cells. All these data suggest that the
difference of activity of TM FGF1 for cell survival between our study
and the Fu et al. report [25] could result not only from differences in
cell type (PC12 / thymocytes) butmore probably fromdifferentmodes
of action of exogenously added FGF1 and endogenously translated
FGF1.
In rat embryonic ﬁbroblasts, FGF1 inhibits both p53-dependent
apoptosis and cell growth arrest through an intracrine pathway [18].
In these cells, overexpression of FGF1WTβ blocks the p53 pathway at
two levels: (i) FGF1 increases MDM2 expression, which is associated
with an acceleration of p53 degradation; (ii) FGF1 decreases p53-
dependent transactivation of the pro-apoptotic gene bax. In PC12
cells, addition of exogenous WTα FGF1 in presence of heparin (which
Fig. 6. Nuclear FGF1 inhibits p53-dependent apoptosis. Left panel: in native PC12 cells and in FGF1 TM transfected PC12 cell lines, DNA damages (stress) induce p53 phosphorylation
and p53-dependent transactivation of proapoptotic genes like puma and noxa. Then, the BH3-only members of Bcl-2 family (Puma and Noxa) activate mitochondrial membranes
depolarization, mitochondrial cytochrome c release in the cytosol and the formation of the apoptosome (cytochrome c, Apaf-1 and Procaspase-9). Finally, the apoptosome initiates
the caspase cascade (caspase-9 and caspase-3 cleavage and activation) and cell death process. Right panel: in FGF1 WT (α and β) PC12 transfected cell lines, FGF1 WT can be
translocated in the nuclear compartment and interacts with p53, in contrast to FGF1 TM (left panel). Nuclear FGF1 WT inhibits p53 phosphorylation and p53-dependent puma
transactivation after DNA damages. This inhibition results in a decrease of the mitochondrial apoptotic pathway and in the absence of caspase-3 cleavage. Only nuclear FGF1 inhibits
p53-dependent apoptosis.
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WTα or β FGF1s inhibits p53-dependent apoptosis at different levels
by direct and/or indirect interactions ([14] and the present study,
Fig. 6). In PC12 cells, we have shown that: (i) in presence of DNA
damages, FGF1 decreases phosphorylation of p53 on its serine 15
(which is associated with p53 stabilization and trans-activation
properties); (ii) FGF1 decreases p53-dependent trans-activation of
the pro-apoptotic genes such as puma and noxa; (iii) FGF1 decreases
mitochondrial depolarization and caspase cascade activation (cas-
pase-9 and -3); (iv) FGF1 nuclear translocation is required for these
different activities; and last (v) only wild type FGF1 co-immunopre-
citates with p53. Our results on ﬁbroblasts and PC12 cells suggest that
FGF1 may block the p53 pathway at multiple levels in different cell
types (ﬁbroblasts versus neuroendocrine cells). Nevertheless, all of
FGF1 actions lead to a decrease of both p53 stability and p53-
dependent transactivation of pro-apoptotic genes. Our data also
suggest that direct and/or indirect interactions between p53-
dependent and FGF1-dependent pathways are taking place in the
nuclear compartment. In this study, we present for the ﬁrst time
evidences that FGF1 nuclear translocation is required for its
neurotrophic and survival activities. We also present the ﬁrst
evidence of interaction between p53 and FGF1 by immunoprecipita-
tion experiment. Most of p53-interacting proteins previously charac-
terized are involved in the regulation of the stability and/or the
transcriptional activity of p53 (MDM2, kinases, acetylases, transcrip-
tional factors, …) [28,29]. However, some p53-interacting proteins
could be involved in transcriptional-independent activities of p53
(Bax, Bak, Bcl-2, Bcl-XL, Puma, …) [30,31]. Only wild type FGF1 is
found interacting with p53 suggesting that FGF1 interacts with p53 in
the nuclear compartment to decrease its stability and its transcrip-
tional activity.
This study must be pursued to progress in the comprehension of
the nuclear activities of FGF1 and the relevance of the interaction
between p53 and FGF1. In PC12 cells, FGF1 could be extracted withnucleoplasmic proteins associated with DNA (personal data) as the
transcription factor p53 is. Is the interaction between FGF1 and p53 at
the transcriptional level? Could FGF1 act as a transcription factor or
co-factor? Wiedlochka and collaborators [19] presented evidences
that FGF1 is phosphorylated by PKCδ in the nuclear compartment. Is
this phosphorylation regulating the activity of this factor in the
nucleus and/or its interaction with p53? In the next few years,
answering these different questionswill be required to progress in the
characterization of the FGF1 intracrine pathway which is involved in
major cellular events such as proliferation, differentiation and cell
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